System Formulary Update
Integrase Strand Transfer Inhibitors (INSTIs)
Situation
The Integrase Strand Transfer Inhibitors class review and formulary standardization was approved at the April 2021 System Pharmacy and Therapeutics Committee meeting.
Background
The following medications were reviewed: dolutegravir, raltegravir, bictegravir, elvitegravir, and combination preparations of the aforementioned agents.
Assessment/Recommendations
Changes Effective: Tuesday July 27, 2021
System P&T voted to include the following products on the UNC Health System Drug Formulary:
As a result, the following products will be removed from the inpatient drug formulary: